The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

Lenacapavir-a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences-is now recommended by the World Health ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...